Immunome, Inc. (IMNM) News
Track canonical SquawkNews coverage tagged to IMNM, Immunome, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 11 indexed stories across 9 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
HC Wainwright & Co. maintained Immunome $40 price target
MACRO | Sep 10, 2026, 01:43 PM UTC
L
Immunome compensation committee grants inducement under Nasdaq Rule 5635(c)(4)
Immunome, Inc. said its Compensation Committee approved inducement grants under Nasdaq Listing Rule 5635(c)(4) on September 1, 2026.
EQUITY | Sep 08, 2026, 08:02 PM UTC
L
Immunome to present at H.C. Wainwright 28th conference on Sept. 14, 2026
Immunome management will present at H.C. Wainwright’s 28th Annual Global Investment Conference on September 14, 2026, according to a company announcement.
EQUITY | Sep 02, 2026, 11:45 AM UTC
L
Immunome Q2 EPS $(0.65) Misses $(0.52) Estimate
Immunome (NASDAQ: IMNM ) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.52) by 25 percent. This is a 30 percent decrease over losses of $(0.50) per share from the same p
EARNINGS | Aug 11, 2026, 08:34 PM UTC
H
SpaceX, Teradata, Pinterest And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures gaining around 100 points on Wednesday. Shares of Space Exploration Technologies Corp (NASDAQ: SPCX ) fell sharply in pre-market trading after the company
EARNINGS | Aug 05, 2026, 12:03 PM UTC
L
ARGX raise PT slightly to $1182 - IMNM is a high-PoS opportunity @ Citi
ARGX raise PT slightly to $1182 - IMNM is a high-PoS opportunity @ Citi
EQUITY | Jul 21, 2026, 10:41 AM UTC
L
IMNM Immunome announces first patient dosed in phase 1 trial evaluating im-3050, an fap-targeted radioligand therapy, in patients with fap-e
IMNM Immunome announces first patient dosed in phase 1 trial evaluating im-3050, an fap-targeted radioligand therapy, in patients with fap-expressing advanced solid tumors Immunome - phase 1 trial to evaluate safety and
EQUITY | Jul 20, 2026, 11:31 AM UTC
L
Immunome Says FDA Accepted NDA for Desmoid Tumors Drug
() -- Immunome (IMNM) said Wednesday that the US Food and Drug Administration has accepted its new drug application for varegacestat, intended to treat adults with desmoid tumors. The agency assigned a Prescription Drug
REGULATION | Jul 08, 2026, 12:06 PM UTC
L
Immunome's NDA for varegacestat in desmoid tumors accepted by FDA
Immunome announced the FDA has accepted its New Drug Application, or NDA, for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor, or GSI, for the treatment of adults with desmoid tumors. The FDA
CENTRAL_BANK | Jul 08, 2026, 11:33 AM UTC
L
Immunome Insider Sold Shares Worth $2,412,522, According to a Recent SEC Filing
() -- Isaac Barchas, Director, on July 06, 2026, sold 100,000 shares in Immunome (IMNM) for $2,412,522. Following the Form 4 filing with the SEC, Barchas has control over a total of 211,763 common shares of the company,
REGULATION | Jul 08, 2026, 07:34 AM UTC
L
Immunome Insider Sold Shares Worth $1,244,331, According to a Recent SEC Filing
() -- Robert Lechleider, Chief Medical Officer, on July 02, 2026, sold 55,000 shares in Immunome (IMNM) for $1,244,331. Following the Form 4 filing with the SEC, Lechleider has control over a total of 15,805 common share
REGULATION | Jul 07, 2026, 09:48 PM UTC